National Institutes of Health National Institute on Drug Abuse Intramural Research Program

1
National Institutes of HealthNational Institute
on Drug AbuseIntramural Research Program

• Presented by
• Dr. Linda Porrino
• National Advisory Council Representative, NIDA

May 16, 2007
2
Biomedical Research Center (BRC)
NIDA IRP Located in Baltimore
Move to new facilities will begin Fall, 2007
3
Board of Scientific Directors (BSC)

• Reviews (Previous and Future)

4
Previous BSC Reviews

• January 11, 2007
• Eliot Gardner, Ph.D., Chief, Neuropsychopharmacolo
  gy Section, Chemical Biology Research Branch
• Elliott Stein, Ph.D., Chief, Neuroimaging
  Research Branch
• Yihong Yang, Ph.D., Chief, Physics Units,
  Neuroimaging Research Branch (Tenure Track)

• May 4 5, 2006
• Roy Wise, Ph.D., Chief, Behavioral Neuroscience
  Research Branch
• Yavin Shaham, Ph.D., Chief, Neurobiology of
  Relapse Section, Behavioral Neuroscience Research
  Branch
• Charles Schindler, Ph.D., Preclinical
  Pharmacology Section, Behavioral Neuroscience
  Research Branch
• Eric Moolchan, M.D., Director, Teen Tobacco
  Addiction Research Clinic, Clinical Pharmacology
  and Therapeutics Research Branch

5
Future BSC Reviews

• Fall 2007
• Jean Lud Cadet, M.D., Ph.D., Chief, Molecular
  Neuropsychiatry
• Amy Newman, Ph.D., Chief, Medicinal Chemistry
• Tsung-Ping Su, Ph.D., Chief, Cellular Pathology

6
NIDA IRP Extramural Intramural Sharing Resources
18 Intramural NIDA scientists 145 collaborations
with extramural scientists
7
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn
  Harrison Pope McClean Hospital, Harvard University The collaboration involves the cognitive consequences of long term marijuana Use during 28 days of monitored cannabis abstinence.
  Buddha Paul Armed Forces Institute of Pathology The collaboration characterizes the urinary excretion of cocaine and its major and minor metabolites
  Alex Makriyannis Northwestern University The collaboration entailed the synthesis and purification of 13 deuterated cannabinoids including delta-9-tetrahydrocannabinol and delta-9-tetrahydrocannabivarin for controlled drug administration studies to characterize the disposition of these drugs and metabolites in humans
  Karen Bolla, Department of Neurology, Johns Hopkins Bayview Medical Center This study evaluates sleep disturbance in marijuana withdrawal.
  Hendree Jones Department of Psychiatry, Johns Hopkins University This study investigating voucher incentive therapies for pregnant drug abusers includes three times per week urine and oral fluid, weekly sweat and monthly hair specimen collection of pregnant opiate and cocaine abusing women and meconium, amniotic fluid and urine at birth. This is the first study to monitor pregnant womens drug use throughout pregnancy and to correlate drug exposure to biological markers obtained at birth and maternal and infant outcome measures
8
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn
  Denis Bonnet Sanofi-Aventis, Inc We have a CRADA to study antagonist-elicited cannabis withdrawal in daily cannabis users with the CB1-cannabinoid receptor antagonist, rimonabant. We are investigating changes in brain activation during the development of THC tolerance, during acute and sustained spontaneous and antagonist-elicited cannabis withdrawal, and after acute THC exposure. This will be the first fMRI and neurocognitive evaluation of this new potential treatment for multiple drug addictions.
  Maureen Black University of Maryland School of Medicine This collaboration on Prenatal Drug Exposure Effects on Adolescent Brain and Behavior Development follows neurobehavioral development of a cohort of in utero cocaine and opiate exposed infants through adolescents.
  Rina Eiden Research Institutes on Addiction, SUNY Buffalo This study evaluates neurobiological and behavioral effects of in utero tobacco exposure.
  Santos B. Murty Murty Pharmaceuticals, Inc. SBIR We are evaluating novel therapeutic formulations for marijuana addiction. We are starting with pre-clinical evaluation with the goal of performing controlled agonist administration in human cannabis addicts.
9
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn
  Michael Wagner DHHS, Manchester, NH We are collaborating with these individuals on an evaluation of the pharmacogenomics of ecstasy users.
  Loralie Langman Mayo Clinic We are collaborating with these individuals on an evaluation of the pharmacogenomics of ecstasy users.
  Jeri Ropero-Miller Research Triangle Institute This interesting project involves analysis of cocaine analytes in human hair evaluation of concentration ratios is different hair types, cocaine sources, drug user populations, and surface-contaminated specimens. These data are essential for development of guidelines and federal regulations for hair testing for cocaine exposure in drug treatment, workplace, military and criminal justice applications.
  Barry Lester Womens and Infants Hospital, Brown University We are evaluating tobacco use during pregnancy and infant neurobehavior among Alaskan natives.
  Greg Kirk Johns Hopkins School of Public Health, Dept of Infectious Diseases We are collaborating on the natural history of HIV infection among injection drug users as part of the ALIVE study.
  Kathleen Neville Children's Mercy Hospital Clinics, Kansas City, KA. We are evaluating the pharmacogenomics of codeine metabolism used for pain in pediatric patients with sickle cell disease.
  Godfrey Perlson Hartford Hospital, Hartford, CT We are participating in an fMRI study examining the effects of amphetamine on reward sensitivity, impulsivity, and driving ability.
10
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn Huestis, Marilyn
  Robert Conley Maryland Psychiatric Research Center, University of Maryland We are evaluating the effects of the cannabinoid-1 receptor antagonist, rimonabant on weight and metabolic risk factors in people with schizophrenia.
  Deborah Stewart UC Davis Medical Center This interesting protocol is dealing with the important public health problem of improving the identification of methamphetamine-exposed children.
  Christine Moore Immunalysis, Inc We have a Materials Transfer Agreement with Immunalysis, Inc. to provide us oral fluid collection devices for monitoring of the disposition of drugs in oral fluid in controlled drug administration studies.
  Stephen Wright GW Pharmaceuticals, Inc. We are developing a Materials Transfer Agreement with GW Pharmaceuticals, Inc. to supply us with a new cannabis based plant extract for an fMRI study of the effects of Sativex and oral THC on attention, affect, working memory, reversal learning, physiology and brain activation. Sativex is oromucosally delivered and the FDA has accepted the application for phase III trials for analgesia in cancer patients.
11
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Newman, Amy Newman, Amy Newman, Amy Newman, Amy
       
  Dr. Chuck Ashby St. Johns University D3 receptor ligands
       
  Dr. Selena Bartlett Ernest Gallo Clinic and Research Center D3 antagonists
       
  Dr. Randy Blakely Vanderbilt University SERT probes
       
  Dr. Wayne Bowen Brown University Sigma receptor ligands
       
  Dr. S. Barak Caine Harvard University Dopamine D3 receptor ligands
       
  Dr. Jeff Conn Vanderbilt University mGluR allosteric modulators
       
  Dr. Natalie Eddington University of MD PK studies on DAT inhibitors
12
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Newman, Amy Newman, Amy Newman, Amy Newman, Amy
  Dr. Greg Elmer University of MD Mouse genetic studies with dopaminergic compounds
       
  Dr. Ron Hammer Tufts University Dopamine D3 receptor ligands
       
  Dr. Jonathan Javitch Columbia University DAT and D2 receptor probes
       
  Dr. Bruce Jenkins Harvard University Dopamine D3 receptor ligands
       
  Dr. Jay Justice Emory University DAT probes
       
  Dr. John Lever University of Missouri Radioiodination of DAT probes
       
  Dr. Robert Luedtke University of No. Texas Dopamine D3/D2 receptors ligands
       
  Dr. Michael Nader Wake Forest University Dopamine D3 receptor ligands
13
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Newman, Amy Newman, Amy Newman, Amy Newman, Amy
  Dr. George Ricaurte Johns Hopkins Medical School DAT and SERT neurotoxins
       
  Dr. Neil Richtand University of Cincinnati Dopamine D3 receptor ligands
       
  Dr. Roger Spealman Harvard University Dopamine D3 receptor ligands
       
  Dr. Christopher Surratt Duquesne University DAT inhibitors
       
  Dr. Peter Thanos Brookhaven Dopamine D3 receptor ligands
       
  Dr. Roxanne Vaughan University of N. Dakota DAT probes
       
  Dr. Harel Weinstein Weill Medical College of CORNELL University DAT and GPCR molecular modeling
       
  Dr. James Woods University of Michigan Dopamine D3 receptor ligands
14
NIDA IRP Extramural Intramural Sharing Resources
(continued)
Newman, Amy Newman, Amy Newman, Amy Newman, Amy
  Dr. Jeff Dalley University of Cambridge, Department of Experimental Psychology D3 receptor antagonists
       
  Dr. Ulrik Gether The Panum Institute, Denmark DAT probes
       
  Dr. Uri Shalev Concordia University D3 receptor antagonists
       
  Dr. Harald Sitte Medical University of Vienna, Austria DAT probes
       
  Dr. Jeff Dalley University of Cambridge,Department of Experimental Psychology D3 receptor antagonists
15
Irving Sunshine Award 2007- Presented to Marilyn
A. Huestis, Ph.D.

• Marilyn A. Huestis, Ph.D., Chief of Chemistry and
  Drug Metabolism Section, Clinical Pharmacology
  and Therapeutics Research Branch, was recently
  selected for the prestigious Irving Sunshine
  Award from the International Association of
  Therapeutic Drug Monitoring and Clinical
  Toxicology (IATDMCT). This award is presented no
  more than every two years to a scientist who has
  made outstanding contributions in the field of
  Clinical Toxicology. The award is named after one
  of the key founding figures in the discipline of
  toxicology and is recognition of work that
  maintains the fine tradition of the science of
  Clinical Toxicology. The presentation will be
  made as part of the opening ceremony of the
  biannual Congress in Nice, September, 2007.

16
Smissman Award 2007- Presented to Kenner Rice,
Ph.D.,

• The Bristol-Myers Squibb Smissman Award This
  award was established in honor of Professor
  Edward E. Smissman of the University of Kansas,
  on the occasion of his untimely death in 1974.
  The Smissman Award is presented in odd years by
  the Division of Medicinal Chemistry at the Fall
  National Meeting of the American Chemical
  Society. It is given to a living scientist whose
  research, teaching or service has had a
  substantial impact on the intellectual and
  theoretical development of the field of Medicinal
  Chemistry. Normally, the award is intended for
  scientists relatively late in their active
  scientific careers where upon a substantial body
  of creative work is available, and sufficient
  time has passed to put their work in perspective.

17
NIDA IRP 2007 Initiatives

1. Viral gene delivery Core
2. Mitochondrial Diseases Program
3. Obesity Program
4. EMA Program